Does a stem cell transplant attack cancer directly?

Usually not. The National Cancer Institute describes stem cell transplants as "procedures that restore blood stem cells in people who have had theirs destroyed by the high doses of chemotherapy or radiation therapy."

The transplant is a rescue, not a weapon. Understanding that changes how the whole treatment makes sense.

What is actually killing the cancer

The treatment doing the work is what comes first. NCI describes it as "treatment with high doses of chemotherapy and maybe radiation therapy," running for "a week or two." That phase is called conditioning.

Those doses are far above what a person could normally survive. The reason is bone marrow. Marrow makes red cells, white cells, and platelets, and it is exquisitely sensitive to chemotherapy. Push the dose high enough to be sure of the cancer and you wipe out marrow too, which by itself would be fatal.

The transplant solves that. Healthy blood stem cells go in afterward through a vein, travel to the marrow space, and rebuild the blood system from scratch. Without that step, the high doses could not be given at all. So the transplant is what makes the real treatment possible.

Whose cells you get changes the answer

NCI describes two kinds. In an autologous transplant, "the stem cells come from you, the person with cancer." They are collected before conditioning and given back afterward. In an allogeneic transplant, "the stem cells come from someone else."

That difference is not just logistics. It decides whether the transplant fights the cancer at all.

The exception, and why it exists

With a donor transplant, something extra can happen. NCI explains it "because of an effect called graft-versus-tumor or graft-versus-leukemia, which can occur after transplants that use stem cells from a donor." Donor white blood cells recognize leftover cancer cells as foreign and attack them.

This is a genuine anti-cancer effect, and it is the one time the answer to this question is yes. It cannot happen with an autologous transplant, because your own immune cells never treated your cancer as foreign in the first place.

The same effect has a dark side

Donor cells do not stop at the cancer. NCI warns that "graft-versus-host disease can occur when white blood cells from your donor (the graft) see cells in your body (the host) as foreign and attack them."

Graft-versus-tumor and graft-versus-host disease are two faces of one biological fact: the new immune system did not grow up in your body and does not recognize all of it. Teams spend a great deal of effort trying to keep the useful half while limiting the harmful half.

What to ask

The single most useful question is which type of transplant is planned, autologous or allogeneic. Almost everything else follows from that answer: whether graft-versus-tumor is part of the strategy, whether graft-versus-host disease is a risk, whether a donor search is needed, and how long the recovery is likely to run.

It is also worth asking what the conditioning regimen is and how many days it takes, since that phase, not the infusion, is the one that will make you feel the worst.